From the 4c……..two significant payments in this quarter: one for the initiation of the CardioCel ® aortic heart valve reconstruction study, and another for the manufacture of the HPV therapeutic vaccine.
……..Admedus anticipates this (the net cash decrease) to be reduced in the December quarter.
Add to these ‘activities requiring significant payments’ the pilot studies for vascular procedures in 2016 and the next Dura mater study.
May not be as sexy ( or costly) as building aortic valves, but will still take extra $. December q may be better, but there may be the need for more (not dissimilar) spending in the q’s beyond.
Don’t think it is over yet.
However, while the difference between staff cost and revenue increased (not in a good way), it is not as bad as it has been.
Ann: Appendix 4C - quarterly, page-98
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.50 |
Change
0.070(0.61%) |
Mkt cap ! $243.1M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.32 | $90.21K | 7.885K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53 | $11.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 2061 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |